- Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trialRen, S.; Wang, X.; Han, B.; Pan, Y.; Zhao, J.; Cheng, Y.; Hu, S.; Liu, T.; Li, Y.; Cheng, Y.; Feng, J.; Yi, S.; Gu, S.; Gao, S.; Luo, Y.; Liu, Y.; Liu, C.; Duan, H.; Zhou, C.; Fan, J.
- First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trialZhou, C.; Cheng, Y.; Chen, J.; Xu, X.; Chen, G.; Pan, Y.; Fang, Y.; Wang, Q.; Huang, Y.; Yao, W.; Wang, R.; Li, X.; Zhang, W.; Zhang, Y.; Shi, J.; Cao, P.; Wang, D.; Lv, D.; Luo, H.; Yang, Z.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 2
- Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory researchZhao, Y.; Liu, J.; Li, X.; Li, Y.; Pu, H.; Wang, X.; Yang, M.; Bai, S.; Guo, L.; Zhao, L.; Zhang, M.; Zhao, H.; Xu, S.; Wang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
会议论文
Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)
2被引15阅读
